Azura Ophthalmics
Developing an innovative portfolio of compounds to advance treatments for Meibomian gland dysfunction , the leading cause of Dry Eye Disease.
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
* | N/A | Grant | |
| Total Funding | 000k | ||
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads